Terry McGuire is a co-founder and general partner of Polaris Venture Partners based in the Boston office. McGuire focuses on life sciences investments.
Prior to starting Polaris, McGuire spent seven years as a partner at the venture capital firm Burr, Egan, Deleage & Co. investing in early stage medical and information technology companies. McGuire was also a partner at Beta Partners from 1988- 1997. His venture capital career began at Golder, Thoma & Cressey in Chicago.
Through the years, McGuire has invested in a number of companies spanning several industries. These investments include Akamai, Aspect Medical Systems, Cubist Pharmaceuticals, GlycoFi, Transform Pharmaceuticals, and Remon Medical Technologies. Akamai is a internet service that deals with Web interactions, and works to improve effective connections. Today, Akamai is a public company. Another example is GlycoFi, which creates biotheraputics through proteins. GlycoFi was acquired by Merck in 2006.
McGuire has co-founded three companies: Inspire Pharmaceuticals, AIR (Advanced Inhalation Research, Inc.), and MicroCHIPS. For example, AIR has created a drug delivery method that allows drugs to be inhaled into the lungs.
Contents |
McGuire is currently a member and formerly the 2009 - 2010 Chairman of the The National Venture Capital Association, the largest organization of venture capital firms in the United States.[1] McGuire is also the Chair of the board of overseers at the Thayer School of Engineering at Dartmouth College.[2] He also serves on the boards of MIT’s The David H. Koch Institute for Integrative Cancer Research, and The Arthur Rock Center for Entrepreneurship at HBS.
McGuire also represents Polaris on the boards of directors of a number of the firm's portoflio companies including Acceleron Pharma, AdiMAB, Arsenal Medical, Ironwood Pharmaceuticals, Life Line Screening, MicroCHIPS, Pulmatrix, Tempo Pharmaceuticals and Trevena.
McGuire is a recipient of the Albert Einstein Award for Outstanding Achievement in the Life Sciences, awarded by Forbes/Gottlieb Medical Technology Investor, Harvard MIT Biomedical Engineering Center, the New Jerusalem Foundation, the Jerusalem Development Authority, and Rodman and Renshaw. He was listed in Forbes - The Midas 100 of Top Tech Investors for 2011.[3] TheFunded ranked McGuire its most loved VC.[4]
McGuire received an MBA from Harvard Business School in 1985. Prior to attending Harvard Business School, he earned his MS in engineering from the Thayer School of Engineering at Dartmouth College. He became a Thomas J. Watson fellow in 1979. McGuire earned his BS in physics and economics from Hobart College.
|
|||||||||||||